Novartis India
NOVARTIND · Retail > Trading · Chairman: C Snook · MD: Sanjay Murdeshwar · Listing date: Nov. 9, 2000 · Employees: 539 · Mumbai · http://www.novartis.in

Stock Price vs Company Growth
1d
0.2%
1w
4.4%
1m
7.9%
3m
24.0%
6m
28.5%
1y
12.0%
all
5.3%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

769 0.2%
768
1,020
Company Overview

Sales
354 Cr
Growth: 0.3%
Profit after Tax
86.3 Cr
Growth: -1.3%
Small Cap
1,899 Cr
P/E: 22.0x
Industry P/E: 22.4x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 354
Growth 0.3%
EBITDA 22.3%
P/S 5.4x
Dividend 1.1%
P/E 22.0x
Book Value ₹ 331
PEG Ratio 76.1x
ROE 11.1%
P/B 2.3x
Shareholding Pattern

Institutions
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Sep22Mar23Sep23Dec23Jun24Sep24Dec24
Promoters
Novartis Ag
70.68 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Sep22Mar23Sep23Dec23Jun24Sep24Dec24
Others
Atul Limited
1.52 %
Iepf
0.47 %
Llp, Partnership Firm, Directors' Relative
0.14 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Sep22Mar23Sep23Dec23Jun24Sep24Dec24
Increase    Decrease    No change
Company Profile Detailed

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
Investors (7)
Followers (1)